| Identification | Back Directory | [Name]
VVD-130037 | [CAS]
3034880-93-5 | [Synonyms]
VVD-130037
VVD-130037 ( BAY-3605349 )
1-[(3R)-3-[3-(4-aminopyrimidin-2-yl)-5-chlorophenyl]-1,4-oxazinan-4-yl]prop-2-en-1-one | [Molecular Formula]
C17H17ClN4O2 | [MOL File]
3034880-93-5.mol | [Molecular Weight]
344.8 |
| Chemical Properties | Back Directory | [Boiling point ]
529.845±50.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.318±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
4.041±0.10(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
VVD-130037 (BAY-3605349) is an orally active covalent activator of KEAP 1 (Kelch-like ECH-associated protein 1) with anti-tumor activity. VVD-130037 degrades NRF2 (nuclear factor-erythroid 2 p45-related factor 2), resulting in significant inhibition of tumor growth in advanced solid tumors[1][2][3]. | [References]
[1] Chan Shan, et al. The Crosstalk between Autophagy and Nrf2 Signaling in Cancer: from Biology to Clinical Applications. Int J Biol Sci. 2024 Nov 11;20(15):6181-6206. DOI:10.7150/ijbs.103187
[2] Gu X, et al. The Cancer Antioxidant Regulation System in Therapeutic Resistance. Antioxidants (Basel). 2024 Jun 27;13(7):778. DOI:10.3390/antiox13070778
[3] Han B, et al. Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer. Cell Rep. 2024 Jul 23;43https://pubmed.ncbi.nlm.nih.gov/39003742/(7):114507. DOI:10.1016/j.celrep.2024.114507 |
|
| Company Name: |
ChemOrigin Pharm
|
| Tel: |
021-15026428026 15026428026 |
| Website: |
chemorigin.com/ |
|